Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
H Alchalby, A Badbaran, T Zabelina… - Blood, The Journal …, 2010 - ashpublications.org
Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become
a reasonable treatment option for patients with advanced myelofibrosis. The role of …
a reasonable treatment option for patients with advanced myelofibrosis. The role of …
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
N Kröger, A Badbaran, E Holler, J Hahn, G Kobbe… - Blood, 2007 - ashpublications.org
Abstract The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and
might be a reliable marker to monitor residual disease after allogeneic stem cell …
might be a reliable marker to monitor residual disease after allogeneic stem cell …
[HTML][HTML] Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F: WT JAK2 ratio in patients with high allele …
S Verstovsek, HM Kantarjian, AD Pardanani, T Burn… - Blood, 2008 - Elsevier
Background: Activating mutations in the pseudokinase domain of JAK2 occur at a high
frequency in Philadelphia chromosome-negative myeloproliferative disorders (MPDs) …
frequency in Philadelphia chromosome-negative myeloproliferative disorders (MPDs) …
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
P Guglielmelli, G Barosi, G Specchia… - Blood, The Journal …, 2009 - ashpublications.org
A total of 186 patients with primary myelofibrosis (PMF) were genotyped for JAK2 V617F at
diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden …
diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden …
[HTML][HTML] Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation
N Kröger, V Panagiota, A Badbaran, T Zabelina… - Biology of Blood and …, 2017 - Elsevier
Molecular genetics may influence outcome for patients with myelofibrosis. To determine the
impact of molecular genetics on outcome after allogeneic stem cell transplantation, we …
impact of molecular genetics on outcome after allogeneic stem cell transplantation, we …
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
G Barosi, G Bergamaschi, M Marchetti… - Blood, The Journal …, 2007 - ashpublications.org
Few investigators have evaluated the usefulness of the JAK2 V617F mutation for explaining
the phenotypic variations and for predicting the risk of major clinical events in primary …
the phenotypic variations and for predicting the risk of major clinical events in primary …
Impact of molecular residual disease post allografting in myelofibrosis patients
C Wolschke, A Badbaran, T Zabelina… - Bone Marrow …, 2017 - nature.com
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
JY Spiegel, C McNamara, JA Kennedy… - Blood …, 2017 - ashpublications.org
In myelofibrosis (MF), driver mutations in JAK2, MPL, or CALR impact survival and
progression to blast phase, with the greatest risk conferred by triple-negative status …
progression to blast phase, with the greatest risk conferred by triple-negative status …
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia …
The clinical relevance of JAK2V617F allele burden in primary myelofibrosis (PMF) has not
been previously studied. Bone marrow-derived DNA from 199 patients with PMF was …
been previously studied. Bone marrow-derived DNA from 199 patients with PMF was …
[HTML][HTML] JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of …
T Lange, A Edelmann, U Siebolts, R Krahl… - …, 2013 - ncbi.nlm.nih.gov
The risk profile and prognosis of patients with myelofibrosis is well described by the
Dynamic International Prognostic Scoring System risk categorization. Allogeneic stem cell …
Dynamic International Prognostic Scoring System risk categorization. Allogeneic stem cell …